Oppenheimer Maintains Outperform on Humana, Raises Price Target to $525

Oppenheimer analyst Michael Wiederhorn has maintained an 'Outperform' rating on Humana (NYSE: HUM) and increased the price target from $475 to $525. This adjustment reflects a positive outlook on the company's performance.